Annotation Detail
Information
- Associated Genes
- PTEN
- Associated Variants
-
PTEN MUTATION
PTEN MUTATION - Associated Disease
- head and neck squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1467
- Gene URL
- https://civic.genome.wustl.edu/links/genes/41
- Variant URL
- https://civic.genome.wustl.edu/links/variants/510
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Head And Neck Squamous Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Taselisib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 26589432
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Taselisib | Resitance or Non-Reponse | true |